Prostate motion during radiotherapy treatment delivery may shift the tumour outside the beam, simultaneously reducing target dose and exposing normal tissues to potentially damaging radiation doses. SPARK seeks to validate the use of Kilovoltage Intrafraction Monitoring (KIM) to manage intrafraction motion in the Stereotactic Body Radiotherapy (SBRT) treatment of low to intermediate risk cases of prostate cancer. SPARK is a phase II multicentre, single armed, two stage study that will measure cancer targeting accuracy and patient outcomes in 48 prostate cancer patients treated with a novel cost effective real-time targeting radiotherapy technology developed and pioneered in Australia.
Project status: Results have now been published. Now closed to recruitment. Reached full accrual of 48 patients in March 2018.
Study size: 48 prostate cancer patients
Site: Multi-site
Collaborating group: TROG Cancer Research
Contact: Doan Trang Nguyen [email protected]